Werewolf Therapeutics, Inc.
200 Talcott Ave
2nd Floor
Watertown, MA 02472
United States
(617) 952-0555
https://werewolftx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 47
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, President, Secretary & Director | 928.26k | 無 | 1964 |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Secretary | 662.99k | 無 | 1958 |
| Dr. Randi Isaacs M.D. | Chief Medical Officer | 702.43k | 無 | 1956 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | 343.43k | 無 | 1960 |
| Ms. Ellen A. Lubman M.B.A. | Chief Business Officer | 無 | 無 | 1976 |
描述
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
公司管治
截至 無 止，Werewolf Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
